Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

| More on:
A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.

Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:

Gentrack Group Ltd (ASX: GTK)

According to a note out of Bell Potter, its analysts have retained their buy rating on this utilities software company's shares with a trimmed price target of $13.20. This follows the release of a half year result this week that was below expectations. Bell Potter notes that project revenues within utilities dragged slightly against a strong prior period and the phasing of contract wins. Nevertheless, it remains positive on the future and is bullish on Gentrack's ability to maintain customer win momentum. It expects this to support high NRR revenues, which will flow onto ARR. The Gentrack share price is trading at $10.57 on Wednesday afternoon.

ResMed Inc. (ASX: RMD)

A note out of Goldman Sachs reveals that its analysts have retained their conviction buy rating and $49.30 price target on this sleep disorder treatment company's shares. This follows news that Apnimed has had success with its phase 3 trial of a sleep apnoea pill. Goldman Sachs isn't concerned and feels that the share price weakness caused by the news has been an overreaction. It believes that Apnimed's AD109's pill is unlikely to displace CPAP as first line therapy in treating OSA. Particularly given that its initial target opportunity are patients who have refused or have failed CPAP. In light of this, Goldman Sachs remains as bullish as ever on ResMed and its long term zoutlook. The ResMed share price is fetching $38.80 at the time of writing.

TechnologyOne Ltd (ASX: TNE)

Analysts at UBS have retained their buy rating on this enterprise software company's shares with an improved price target of $42.20. According to the note, the broker was impressed with TechnologyOne's half year results. It highlights that annual recurring revenue grew strongly and was in line with its expectations. Whereas its profits were comfortably ahead of its estimates for the half. Combined with its strong net revenue retention rate and ultra low churn levels, it believes the result supports its bullish view on the long term growth outlook of the company. The Technology One share price is trading at $38.46 this afternoon.

Motley Fool contributor James Mickleboro has positions in ResMed and Technology One. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Gentrack Group, Goldman Sachs Group, ResMed, and Technology One. The Motley Fool Australia has positions in and has recommended Gentrack Group and ResMed. The Motley Fool Australia has recommended Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Six smiling office colleagues stand in a row and look at the camera.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

woman holding 'hiring' sign in shop
Broker Notes

How much upside does Macquarie tip for Seek shares?

The broker recently reviewed Australian job ad volumes for May.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Macquarie tips 50% return for this cheap ASX All Ords stock

Let's see which stock the broker is feeling bullish about this week.

Read more »

A woman sits at her home computer with baby on her lap, and the winning ticket in her hand.
Consumer Staples & Discretionary Shares

How much upside does Macquarie expect for Lottery Corporation shares?

This ASX 200 stock has proven resilient through various economic conditions.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Broker Notes

Guess which ASX 300 stock was downgraded to sell today

Bell Potter has become bearish on this stock. But why?

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Broker Notes

Is the ResMed share price still cheap? What the numbers say

Let's see what analysts are saying about this blue chip as it nears a 52-week high.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Broker Notes

What does Macquarie think REA shares are worth?

Top broker Macquarie has reviewed its rating and price target on REA shares.

Read more »

Woman checking out new TVs.
Broker Notes

Does JP Morgan think JB Hi-Fi shares can keep rising?

The retailer is up 16% for the year to date.

Read more »